FrancophonIA/ELRC3.0 huggingface dataset:
English: Interaction studies with these agents have only
Croatian: Ispitivanja interakcija s tim lijekovima provedena su samo u odraslih.
English: Dose adjustment is not considered necessary in subjects with reduced UGT1A1 activity due to genetic polymorphism.
Croatian: Smatra se da nije potrebno prilagođavati dozu lijeka u bolesnika sa smanjenom aktivnošću UGT1A1 enzima zbog
English: Interactions between the components of DUTREBIS and co-administered medicinal products are listed
Croatian: Interakcije između komponenti lijeka DUTREBIS i istodobno primijenjenih lijekova popisane su u
English: The signature mutations decrease viral susceptibility to raltegravir and addition of other mutations results in a further decrease in raltegravir susceptibility.
Croatian: Karakteristične mutacije smanjuju osjetljivost virusa na raltegravir, koja se dodatno smanjuje ako su prisutne i druge mutacije.
English: Lamivudine in the fixeddose combination tablet was bioequivalent with the lamivudine (single agent) after administration of the individual component.
Croatian: Lamivudin u tableti s fiksnom kombinacijom doza bio je bioekvivalentan lamivudinu (pojedinačnom lijeku) primijenjenom samostalno.
English: If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before
Croatian: Ako se bilo što od navedenoga odnosi na Vas (ili ako niste sigurni), obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego što uzmete DUTREBIS.
English: • lactic acidosis - signs include deep, fast, difficult breathing, feeling drowsy, numb or weak arms or legs, feeling or being sick (nausea or vomiting), stomach pain
Croatian: • laktacidozu - znakovi uključuju duboko, ubrzano i otežano disanje, omamljenost, utrnulost ili slabost u rukama i nogama, mučninu ili povraćanje, bol u trbuhu.
English: Nucleoside and nucleotide reverse transcriptase inhibitors have been demonstrated in vitro and in vivo to cause a variable degree of mitochondrial damage.
Croatian: Pokazalo se da nukleozidni i nukleotidni inhibitori reverzne transkriptaze uzrokuju različite stupnjeve oštećenja mitohondrija in vitro i in vivo.
English: If you notice after 6 hours, then skip the intake and take the next doses as
Croatian: Ako je prošlo više od 6 sati, preskočite dozu i sljedeće doze nastavite uzimati prema uobičajenom rasporedu.
English: Thus the data indicate that the major mechanism of clearance of raltegravir in humans is UGT1A1-mediated glucuronidation.
Croatian: Ovi podaci ukazuju na to da je glavni mehanizam klirensa raltegravira u ljudi glukuronidacija posredovana UGT1A1 enzimom.
English: Administration of lamivudine at very high dose levels in acute animal studies did not result in any organ toxicity.
Croatian: U ispitivanjima akutne primjene na životinjama primjena lamivudina u vrlo visokim dozama nije dovela do oštećenja bilo kojeg organa.
English: Co-administration of rifampicin with DUTREBIS is not recommended.
Croatian: Istodobna primjena rifampicina s lijekom DUTREBIS se ne preporučuje.
English: In HIV-infected patients with severe immune deficiency at the time of initiation of CART, an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.
Croatian: U bolesnika inficiranih HIV-om s teškom imunodeficijencijom u trenutku uvođenja kombinirane antiretrovirusne terapije može se razviti upalna reakcija na asimptomatske ili rezidualne oportunističke infekcije.
English: CART has been associated with redistribution of body fat (lipodystrophy) in HIV patients including the loss of peripheral and facial subcutaneous fat, increased intra-abdominal and visceral fat, breast hypertrophy and dorsocervical fat accumulation (buffalo hump).
Croatian: U bolesnika inficiranih HIV-om, kombinirana antiretrovirusna terapija povezuje se s preraspodjelom masnog tkiva u tijelu (lipodistrofija), uključujući gubitak perifernog i facijalnog potkožnog masnog tkiva, porast intraabdominalnog i visceralnog masnog tkiva, hipertrofiju dojki i nakupljanje masnog tkiva u dorzocervikalnom području (bivolja grba).
English: Caution should be used when administering DUTREBIS in patients with a pre-existing history of depression or psychiatric
Croatian: Potreban je oprez kada se DUTREBIS primjenjuje u bolesnika s depresijom ili psihijatrijskom bolešću u anamnezi.
English: STARTMRK (multi-centre, randomised, double-blind, active-control study) evaluated the safety and anti-retroviral activity of raltegravir 400 mg twice daily vs. efavirenz 600 mg at bedtime, in a combination with emtricitabine (+) tenofovir, in treatment-naïve HIV-infected patients with HIV RNA > 5,000 copies/ml.
Croatian: U ispitivanju STARTMRK (multicentrično, randomizirano, dvostruko slijepo, aktivnim lijekomkomparatorom kontrolirano ispitivanje) ocjenjivali su se sigurnost i antiretrovirusna aktivnost raltegravira u dozi od 400 mg dvaput na dan naspram efavirenza u dozi od 600 mg primijenjenog navečer prije spavanja, u kombinaciji s emtricitabinom (+) tenofovirom u bolesnika s HIV infekcijom i > 5000 HIV-RNK kopija/ml koji prethodno nisu bili liječeni.
English: Co-administration of DUTREBIS with antacids containing divalent metal cations may reduce raltegravir absorption by chelation, resulting in a decrease of raltegravir plasma levels.
Croatian: Istodobna primjena lijeka DUTREBIS s antacidima koji sadrže dvovalentne katione metala može kelacijom smanjiti apsorpciju raltegravira i tako dovesti do sniženja koncentracije raltegravira u plazmi.
English: DUTREBIS should not be used in children below 6 years of age or in patients weighing less than 30 kg due to weight based dosing requirements in this patient population (see section 5.2).
Croatian: DUTREBIS se ne smije primjenjivati u djece mlađe od 6 godina niti u bolesnika tjelesne težine manje od 30 kg jer se u toj populaciji bolesnika doziranje treba odrediti na temelju tjelesne težine (vidjeti
English: For raltegravir, renal clearance of unchanged drug is a minor pathway of elimination.
Croatian: Klirens nepromijenjenog lijeka putem bubrega manje je važan put eliminacije raltegravira.
English: At 240-weeks, in treatment-naïve patients, Grade 2 or higher laboratory abnormalities that represent a worsening Grade from baseline of AST, ALT or total bilirubin occurred in 22 %, 44 % and 17 %, respectively, of co-infected subjects treated with raltegravir as compared to 13 %, 13 % and 5 % of all other subjects treated with raltegravir.
Croatian: Nakon 240 tjedana su, u bolesnika koji do tada nisu bili liječeni, odstupanja u laboratorijskim nalazima AST-a, ALT a i ukupnog bilirubina 2. ili višeg stupnja koja su predstavljala pogoršanje u odnosu na početne vrijednosti zabilježena u 22%, 44% odnosno 17% ispitanika s istodobnom infekcijom koji su liječeni raltegravirom, u odnosu na 13%, 13% odnosno 5% svih ostalih ispitanika liječenih
English: There were no clinically important pharmacokinetic differences between patients with severe renal insufficiency
Croatian: U odraslih nije bilo klinički značajne razlike u farmakokinetici lijeka između bolesnika s teškom insuficijencijom
English: Co-administration of DUTREBIS with aluminium and/or magnesium antacids is not recommended (see section 4.5).
Croatian: Istodobna primjena lijeka DUTREBIS s antacidima koji sadrže aluminij i/ili magnezij se ne preporučuje (vidjeti dio 4.5).
English: No evidence of mutagenicity or genotoxicity was observed in in vitro microbial mutagenesis (Ames) tests, in vitro alkaline elution assays for DNA breakage and in vitro and in vivo chromosomal aberration studies conducted with raltegravir.
Croatian: U in vitro testovima mutageneze na mikroorganizmima (Amesov test), in vitro testovima alkalne elucije radi utvrđivanja oštećenja DNK te in vitro i in vivo istraživanjima kromosomskih aberacija nisu otkriveni znakovi mutagenosti ili genotoksičnosti raltegravira.
English: Patients should be advised to seek medical advice if they experience joint aches and pain, joint
Croatian: Bolesnike treba uputiti da potraže liječničku pomoć osjete li bolove u zglobovima, ukočenost zglobova ili poteškoće pri kretanju.
English: From the clinical studies, a large proportion of patients used atazanavir and / or tenofovir, both agents that result in increases in raltegravir plasma levels, in the optimised background regimens.
Croatian: Veliki udio bolesnika iz kliničkih ispitivanja je u sklopu optimizirane osnovne terapije primao atazanavir i/ili tenofovir, oba lijeka koji povisuju koncentraciju raltegravira u plazmi.
English: Raltegravir at concentrations of 31  20 nM resulted in 95 % inhibition (IC95) of HIV-1 replication (relative to an untreated virus-infected culture) in human T-lymphoid cell cultures infected with the cell-line adapted HIV-1 variant H9IIIB.
Croatian: U kulturama humanih T-limfoidnih stanica inficiranih sojem H9IIIB virusa HIV-1 prilagođenim za staničnu liniju, raltegravir je u koncentracijama od 31  20 nM izvršio 95%-tnu inhibiciju (IC95) replikacije virusa HIV-1 (u odnosu na netretiranu, virusom inficiranu kulturu).
English: Nucleoside/tide reverse transcriptase inhibitors (NRTIs)
Croatian: Nukleozidni/nukleotidni inhibitori reverzne transkriptaze (NRTI) Interakcija između lijekova nije
English: Overall, considerable inter- and intra-subject variability was observed in the pharmacokinetics of raltegravir (see sections 4.5 and 5.2).
Croatian: Izostanak virološkog odgovora i razvoj rezistencije Sveukupno, opažene su značajne interindividualne i intraindividualne razlike u farmakokinetici raltegravira (vidjeti dijelove 4.5 i 5.2).
English: Myopathy and rhabdomyolysis
Croatian: Miopatija i rabdomioliza
English: Because the extent to which DUTREBIS may be dialyzable is unknown, dosing before a dialysis session should be avoided (see section 4.2).
Croatian: Budući da nije poznato u kojoj se mjeri DUTREBIS može ukloniti dijalizom, treba izbjegavati doziranje lijeka prije dijalize (vidjeti dio 4.2).
English: Taking an aluminium and magnesium antacid within 6 hours of raltegravir administration significantly decreased raltegravir plasma levels.
Croatian: Uzimanje antacida koji sadrži aluminij i magnezij unutar 6 sati nakon primjene raltegravira značajno je snizilo koncentraciju raltegravira u plazmi.
English: Recommendations concerning co-administration with DUTREBIS
Croatian: Preporuke za istodobnu primjenu s lijekom DUTREBIS
English: Patients co-infected with hepatitis C and treated with alpha interferon and ribavirin may constitute a special risk.
Croatian: Taj rizik može biti posebno izražen u bolesnika s istodobnom infekcijom hepatitisom C koji se liječe alfa interferonom i ribavirinom.
English: Muscle pain, tenderness, or weakness have been reported during treatment with raltegravir.
Croatian: Tijekom liječenja raltegravirom prijavljeni su bol, osjetljivost ili slabost u mišićima.
English: Do not stop taking it
Croatian: Nemojte ga prestati uzimati zbog sljedećih razloga:
English: At the NOAEL, systemic exposure was similar to that at the clinical dose of 400 mg twice daily.
Croatian: Pri primjeni najviše doze koja ne uzrokuje štetne učinke (NOAEL) sustavna izloženost bila je slična onoj koja se postiže kliničkom dozom od 400 mg dvaput na dan.
English: In clinical studies, the number of HIV patients taking raltegravir who developed cancer was similar to that of patients taking other HIV medicines.
Croatian: U kliničkim ispitivanjima, rak se razvio u sličnog broja bolesnika s HIV-om liječenih raltegravirom i onih liječenih drugim lijekovima protiv HIV-a.
English: Each film-coated tablet contains 150 mg of lamivudine and 300 mg of raltegravir (as potassium).
Croatian: Jedna filmom obložena tableta sadrži 150 mg lamivudina i 300 mg raltegravira (u obliku raltegravirkalija).
English: Lamivudine demonstrates low cytotoxicity to peripheral blood lymphocytes, to established lymphocyte and monocyte-macrophage cell lines, and to a variety of bone marrow progenitor cells in vitro.
Croatian: Lamivudin pokazuje nisku citotoksičnost za periferne limfocite, diferencirane stanične linije limfocita i monocitno-makrofagne linije te brojne preteče stanica iz koštane srži in vitro.
English: • inflammation of liver (hepatitis); When hepatitis causes symptoms, they can include: belly pain; nausea and vomiting; not feeling hungry; jaundice, which is when the skin or
Croatian: Kada je hepatitis uzrok simptoma oni mogu uključivati: bol u trbuhu; mučninu i povraćanje; izostanak osjećaja gladi; žuticu, tj. žutu boju kože ili
English: Therefore, the concomitant use of DUTREBIS with cladribine is not recommended (see section 4.4).
Croatian: Stoga se istodobna primjena lijeka DUTREBIS i kladribina ne preporučuje (vidjeti dio 4.4).
English: Co-administration of other medicinal products
Croatian: Istodobna primjena s drugim lijekovima
English: A slight increase in incidence of supernumerary ribs was observed in rat pups of dams exposed to raltegravir at approximately 4.4-fold human exposure at 400 mg twice daily based on AUC0-24 hr. No development effects were seen at 3.4-fold human exposure at 400 mg twice daily based on AUC0-24 hr (see section 4.6).
Croatian: Zapažen je neznatan porast incidencije prekobrojnih rebara kod mladunčadi štakora kada je izloženost ženke raltegraviru bila približno 4,4 puta veća od izloženosti u ljudi pri dozi od 400 mg dvaput na dan izračunate na temelju AUC0-24h.
English: Patient demographics (gender, age and race) and baseline characteristics were comparable between the group receiving raltegravir 400 mg twice daily and the group receiving efavirenz 600 mg at bedtime.
Croatian: Demografska obilježja (spol, dob i rasa) i početne karakteristike bolesnika u skupini koja je primala raltegravir 400 mg dvaput na dan bili su usporedivi s onima u bolesnika koji su primali efavirenz u dozi od 600 mg navečer prije spavanja.
English: Patient demographics (gender, age and race) and baseline characteristics were comparable between the groups receiving raltegravir 400 mg twice daily and placebo.
Croatian: Demografska obilježja (spol, dob i rasa) i početne karakteristike bolesnika u skupini koja je primala raltegravir 400 mg dvaput na dan bili su usporedivi u onih bolesnika koji su primali placebo.
English: No dosage adjustment is necessary for DUTREBIS based on gender, race, or BMI.
Croatian: Nije potrebno prilagođavati dozu lijeka DUTREBIS na temelju spola, rase ili indeksa tjelesne mase.
English: The combination of lamivudine with cladribine is not-recommended (see section 4.5).
Croatian: Ne preporučuje se kombinacija lamivudina i kladribina (vidjeti dio 4.5).
English: DUTREBIS with cladribine is not recommended.
Croatian: Istodobna primjena lijeka DUTREBIS s kladribinom se ne preporučuje.
English: No dose adjustment required for DUTREBIS or etravirine.
Croatian: Nije potrebno prilagođavati dozu lijeka DUTREBIS ili etravirina.
English: Table 2 Efficacy Outcome at Weeks 48 and 96
Croatian: Ishod djelotvornosti u 48. i 96. tjednu
English: Following oral administration, lamivudine was excreted in breast milk at similar concentrations to
Croatian: Nakon peroralne primjene, lamivudin se izlučuje u majčino mlijeko u koncentracijama koje su slične onima pronađenima u serumu.
English: No dose adjustment required for DUTREBIS or zidovudine.
Croatian: Nije potrebno prilagođavati dozu lijeka DUTREBIS ili zidovudina.
English: DUTREBIS is not recommended for use as monotherapy.
Croatian: Ne preporučuje se primjena lijeka DUTREBIS u monoterapiji.
English: Merck Sharp & Dohme Cyprus Limited Τηλ: 800 00 673 (+357 22866700) cyprus_info@merck.com
Croatian: Merck Sharp & Dohme Cyprus Limited Τηλ: 800 00 673 (+357 22866700)
English: Therefore, DUTREBIS should be used with caution in patients with severe hepatic impairment (see sections 4.4 and 5.2).
Croatian: Stoga DUTREBIS treba primjenjivati uz oprez u bolesnika s teškim oštećenjem funkcije jetre (vidjeti dijelove 4.4 i 5.2).
English: Lamivudine is predominately cleared unchanged by renal excretion.
Croatian: Lamivudin se pretežno izlučuje putem bubrega u nepromijenjenom obliku.
English: If creatinine clearance decreases to <50 ml/min, DUTREBIS should be switched to a regimen of the individual components (lamivudine and raltegravir) (see section 4.2).
Croatian: Ako klirens kreatinina padne na <50 ml/min potrebno je prijeći na režim liječenja pojedinačnim komponentama lijeka DUTREBIS (lamivudinom i raltegravirom) (vidjeti dio 4.2).
English: raltegravir AUC  36 % raltegravir C12hr  21 % raltegravir Cmax  36 %
Croatian: raltegravir AUC  36% raltegravir C12h  21% raltegravir Cmax  36%
English: The major circulating entity was raltegravir and represented approximately 70 % of the total radioactivity; the remaining radioactivity in plasma was accounted for by raltegravir-glucuronide.
Croatian: Glavni cirkulirajući spoj bio je raltegravir koji je činio oko 70% ukupne radioaktivnosti.
English: Tell your doctor, pharmacist or nurse if you notice any of the side effects above.
Croatian: Obavijestite liječnika, ljekarnika ili medicinsku sestru ako primijetite bilo koju gore navedenu
English: Therefore, DUTREBIS should be used with caution in patients with severe hepatic impairment (see sections 4.2 and 5.2).
Croatian: Stoga DUTREBIS treba primjenjivati uz oprez u bolesnika s teškim oštećenjem funkcije jetre (vidjeti dijelove 4.2 i 5.2).
English: One patient experienced drug related clinical adverse reactions of Grade 3 psychomotor hyperactivity, abnormal behaviour and insomnia; one patient experienced a Grade 2 serious drug related allergic
Croatian: Jedan je pedijatrijski bolesnik imao kliničke nuspojave povezane s lijekom: psihomotoričku hiperaktivnost 3. stupnja, neuobičajeno ponašanje i insomniju.
English: Co-administration of raltegravir with aluminium and magnesium antacids resulted in reduced raltegravir plasma levels.
Croatian: Istodobna primjena raltegravira s antacidima koji sadrže aluminij i magnezij rezultirala je sniženim koncentracijama raltegravira u plazmi.
English: See leaflet for further information.
Croatian: Za dodatne informacije pročitajte Uputu o lijeku.
English: Rash occurred more commonly in treatment-experienced patients receiving regimens containing raltegravir + darunavir compared to patients receiving raltegravir without darunavir or darunavir
Croatian: Osip se češće javljao u prethodno liječenih bolesnika čije je liječenje uključivalo raltegravir i darunavir u usporedbi s bolesnicima koji su primali raltegravir bez darunavira ili darunavir bez raltegravira (vidjeti dio 4.8).
English: Co-administration of DUTREBIS with aluminium and/or magnesium containing antacids is not recommended.
Croatian: Istodobna primjena lijeka DUTREBIS s antacidima koji sadrže aluminij i/ili magnezij se ne preporučuje.
English: Each film-coated tablet contains 150 mg of lamivudine and 300 mg of raltegravir (as potassium)
Croatian: Jedna filmom obložena tableta sadrži 150 mg lamivudina i 300 mg raltegravira (u obliku
English: Administration of co-trimoxazole with lamivudine in patients with renal impairment should be carefully assessed.
Croatian: Potrebno je pažljivo procijeniti primjenu kotrimoksazola istodobno s lamivudinom u bolesnika s oštećenom funkcijom bubrega.
English: Durable outcomes (Week 48 and Week 96) for patients on the recommended dose raltegravir 400 mg twice daily from the pooled studies BENCHMRK 1 and BENCHMRK 2 are shown in Table 2.
Croatian: U Tablici 2 prikazani su dugotrajni ishodi (48. i 96. tjedan) liječenja bolesnika koji su primali preporučenu dozu raltegravira 400 mg dvaput na dan, iz objedinjenih ispitivanja BENCHMRK 1 i
English: Ethinyl Estradiol AUC  2 % Ethinyl Estradiol Cmax ↑ 6 % Norelgestromin AUC ↑ 14 % Norelgestromin Cmax ↑ 29 %
Croatian: etinil estradiol AUC  2% etinil estradiol Cmax ↑ 6%
English: • increased liver blood tests; abnormal white blood cells; increased fat levels in blood (such as cholesterol and triglycerides); increased level of enzyme from salivary glands or pancreas
Croatian: povišene razine masnoća u krvi (primjerice kolesterola i triglicerida); povišene vrijednosti enzima iz žlijezda slinovnica ili gušterače.
English: For mean CD4 changes, baseline-carry-forward was used for virologic failures.
Croatian: Za srednje vrijednosti promjene broja CD4 stanica, kod neuspješnog virološkog odgovora preneseni su početni nalazi.
English: • harsh, raspy, or strained voice; nosebleed; nasal congestion
Croatian: • promukao, hrapav ili suhi glas; krvarenje iz nosa; začepljen nos
English: Uncommon (may affect up to 1 in 100 people)
Croatian: Manje česte (mogu se javiti u do 1 na 100 osoba):
English: Merck Sharp & Dohme B.V. Tel: 0800 99 99 000 (+31 23 5153153) medicalinfo.nl@merck.com
Croatian: Tel: 0800 99 99 000 (+31 23 5153153) medicalinfo.nl@merck.com
English: No dose adjustment required for DUTREBIS or maraviroc.
Croatian: Nije potrebno prilagođavati dozu lijeka DUTREBIS ili maraviroka.
English: Do not operate machines, drive or cycle if you feel dizzy after taking this medicine.
Croatian: Ako nakon uzimanja ovog lijeka osjetite omaglicu, nemojte raditi sa strojevima niti upravljati vozilom
English: No animal studies have been conducted with DUTREBIS.
Croatian: Nisu provedena ispitivanja lijeka DUTREBIS na životinjama.
English: Investigations common atypical lymphocytes, elevations in liver enzymes (AST, ALT), blood triglycerides increased, lipase increased, blood pancreatic amylase uncommon absolute neutrophil count decreased, alkaline phosphatase increased, blood albumin decreased, blood amylase increased, blood bilirubin increased, blood cholesterol increased, blood creatinine increased, blood glucose increased, blood urea nitrogen increased, creatine phosphokinase increased, fasting blood glucose increased, glucose urine present, high density lipoprotein increased, international normalised ratio increased, low density lipoprotein increased, platelet count decreased, red blood cells urine positive, waist circumference increased, weight increased, white blood cell count decreased
Croatian: manje često zatajenje bubrega, nefritis, nefrolitijaza, nikturija, bubrežna cista, oštećenje funkcije bubrega, tubulointersticijski nefritis manje često erektilna disfunkcija, ginekomastija, simptomi menopauze astenija, umor, malaksalost, vrućica manje često nelagoda u prsima, zimica, edem lica, nakupljanje masnog tkiva, osjećaj treme, submandibularna nakupina, periferni edem, bol atipični limfociti, povišeni jetreni enzimi (AST, ALT), povišeni trigliceridi u krvi, povišene lipaze, povišene pankreatične amilaze u manje često smanjen apsolutni broj neutrofila, povišena alkalna fosfataza, sniženi albumini u krvi, povišena amilaza u krvi, povišen bilirubin u krvi, povišen kolesterol u krvi, povišen kreatinin u krvi, povišene vrijednosti glukoze u krvi, povišene vrijednosti dušika iz ureje u krvi, povišene vrijednosti kreatin fosfokinaze, povišene vrijednosti glukoze natašte, glukoza u urinu, povišeni lipoproteini visoke gustoće, povećan međunarodni normalizirani omjer (INR), povišeni lipoproteini niske gustoće, smanjen broj trombocita, eritrociti u urinu, povećan opseg struka, porast tjelesne težine, smanjen broj bijelih krvnih stanica
English: • deep, fast, difficult breathing, feeling drowsy, numb or weak arms or legs, feeling or being sick
Croatian: • duboko, ubrzano i otežano disanje, omamljenost, utrnulost ili slabost u rukama ili nogama, mučninu, povraćanje, bol u trbuhu.
English: There have been reports of mitochondrial dysfunction in infants exposed in utero and/or post-natally to nucleoside reverse transcriptase inhibitors (see section 4.4).
Croatian: Prijavljeni su slučajevi disfunkcije mitohondrija u dojenčadi koja je bila izložena nukleozidnim inhibitorima reverzne transkriptaze in utero i/ili po rođenju (vidjeti
English: • buzzing, hissing, whistling, ringing or other persistent noise in the ears • palpitations; slow heart rate; fast or irregular heart beats
Croatian: • lupanje srca (palpitacije); usporeno kucanje srca; ubrzani ili nepravilni otkucaji srca
English: Week 48 and Week 240 outcomes for patients on the recommended dose of raltegravir 400 mg twice daily from STARTMRK are shown in Table 3.
Croatian: U Tablici 3 prikazani su ishodi (48. i 240. tjedna) liječenja bolesnika koji su primali preporučenu dozu raltegravira od 400 mg dvaput na dan u ispitivanju STARTMRK.